DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20172242

Study of the effect of vildagliptin, a DPP-IV inhibitor on learning and memory dysfunction of diabetic rats

Trupti Rekha Swain, Manorama Swain, Suchismita Pattanaik

Abstract


Background: To evaluate whether vildagliptin, DPP-IV inhibitor possess a favorable effect on learning and memory dysfunction in the management of Diabetes mellitus.

Methods: Forty Albino rats of either sex weighing 100-180g, were divided into 4 groups of 10 animals each. Streptozotocin was used for induction of diabetes in rats. The rats were divided into 4 groups of eight rats in each. Group-1 was taken as control with no further intervention whereas group-2,3,4 were injected 5mg/kg, 10mg/kg,20mg/kg of vildagliptin respectively for a period of 2 months. At the end of first and second month of treatment period, the rats were subjected to Y maze and EPM tests. The data were analyzed statistically using one-way analysis of variance followed by Student’s t test for paired analysis.

Results: There was significant decrease in no of arm entries and SAP (p<0.05) in group-1 with induced diabetes. In addition, there was slight increase in no of open arm entries with time spent in open arm for the same group. The decrease in no of arm entries and SAP progressively declined and the no of open arm entries with time spent in open arm progressively increased from group-2 to group 4 till the end of 1st month. After 2nd month there was further decrease in no of arm entries and SAP (p<0.05) for group-1. There was significant increase in all parameters for rest of the groups after 2nd month as compared to 1st month. The findings clearly infer the potency of vildagliptin in treating diabetes induced learning and memory impairment.

Conclusions: Vildagliptin significantly reduces the incidence of diabetes induced memory impairment and improves learning if continued further.


Keywords


Diabetes, DPP- 4 inhibitors, Learning, Memory

Full Text:

PDF

References


F. Pasquier Universite Lille-Nord-de-France Diabetes and cognitive impairment: how to evaluate the cognitive status? Diabetes Metab. 2010 Oct;36(3):S100-5.

Gault V, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol. 2008;587:112-7.

During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173-9.

Abbas T, Faivre E, Ho’ lscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice. interaction between type 2 diabetes and Alzheimer’s disease, Behav Brain Res. 2009 Dec 14;205(1):265-71.

Gault VA, Holscher C. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. J Neurophysiol. 2008;99:1590-5. Mer’s disease. Behav Brain Res 2009.

Pintanaa H, Apaijaia N, Pratchayasakula W, Chattipakorna N, Siriporn C. Chattipakorna B. Chiang Mai University, Chiang Mai, 50200, Thailand DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin resistant rat. (J Endocrinol JOE-12-0521; 2013.

McIntyrea RS, Powellc AM, Kaidanovich- Beiline O, Soczynskac JK, Mohammad A, Woldeyohannesc HO, et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. (Behav Brain Res 2013 Jan 15;237:164-71.

D’Amicoa M, Clara Di F, Marfellab R, Abbatecolab AM, Ferraraccioc F, Francesco R, et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. (Exp Gerontol. 2010 Mar;45(3):202-7.

Dixit TS, Sharma AN, Lucot JB, Elased KM. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiology and Behavior. 2013;114-115:38-41.